Edwards Lifesciences Executive Sells $54K in Stock via Planned Trade

If you've ever wondered what it looks like when a corporate insider makes a calculated stock move, here's a clean example. Daniel J. Lippis, Corporate Vice President of TAVR at Edwards Lifesciences, sold 619 shares of company stock on September 11, 2026, netting roughly $54,168 at $87.51 per share. At the same time, he picked up 619 shares through employee stock options at just $72.68 apiece — a classic exercise-and-sell play that lets an executive lock in the spread between the option price and the current market price.

Before you read too much into it, the whole thing was pre-planned. These transactions were executed under a Rule 10b5-1 trading plan, which is essentially a pre-scheduled agreement that lets insiders set up trades in advance — well before they'd have access to any sensitive company information. That structure exists specifically to remove the appearance (and reality) of insider trading. So no, this isn't a red flag that Lippis thinks the stock is about to tank.

Read more NextEra and Dominion Energy Merger Could Serve 10M Customers →

After both transactions cleared, Lippis still holds more than 40,000 shares of Edwards Lifesciences, meaning he's still very much invested in the company's performance. That's a meaningful stake by any measure, and it signals he's not exactly running for the exits. According to InvestingPro analysis cited at the time of the trades, the stock appeared to be fairly valued even as it traded below the sale price of $87.51.

For everyday investors, insider transactions like this are worth tracking but rarely worth panicking over — especially when they're tied to options exercises rather than pure open-market sales. The real question is always whether the insider is reducing their overall position dramatically, and in this case, holding 40,000-plus shares suggests that's not happening here.

Continue reading at Investing.com